Sanofi/Regeneron Solidify Lead Over J&J/GSK In IL-6 Inhibition For RA
This article was originally published in The Pink Sheet Daily
Executive Summary
With second pivotal trial of Sanofi/Regeneron's sarilumab, companies move towards filing. Johnson & Johnson and GlaxoSmithKline are close behind with sirukumab, aiming for a 2016 filing.
You may also be interested in...
Immuno-Oncology’s ‘Infancy’? ‘Adolescence?’ Wherever You Peg Development, Adverse Event Reporting Needs To Mature
A common toxicity of advanced IO therapies, cytokine release syndrome needs to be better characterized as part of the groundwork for future development of the field, according to Friends of Cancer Research.
Keeping Track: Novel Orphan Drugs Amondys 45, Nulibry Clear US FDA; First-Line NSCLC Claim For Libtayo
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: